Q1 EPS Estimate for Y-mAbs Therapeutics Boosted by Analyst
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Stock analysts at Brookline Capital Management raised their Q1 2025 earnings estimates for shares of Y-mAbs Therapeutics in a research note issued to investors on Tuesday, March 4th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.17) per share for the quarter, […]
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Free Report) – Stock analysts at Brookline Capital Management raised their Q1 2025 earnings estimates for shares of Y-mAbs Therapeutics in a research note issued to investors on Tuesday, March 4th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.17) per share for the quarter, […]
